## **1** Comparison of control and transmission of COVID-19 across epidemic waves in

# 2 Hong Kong: an observational study

- Bingyi Yang<sup>1</sup>, Yun Lin<sup>1</sup>, Weijia Xiong<sup>1</sup>, Chang Liu<sup>1</sup>, Huizhi Gao<sup>1</sup>, Faith Ho<sup>1</sup>, Jiayi Zhou<sup>1</sup>, Ru
- 4 Zhang<sup>1</sup>, Jessica Y. Wong<sup>1</sup>, Justin K. Cheung<sup>1</sup>, Eric H. Y. Lau<sup>1,2</sup>, Tim K. Tsang<sup>1</sup>, Jingyi Xiao<sup>1</sup>,
- 5 Irene O. L. Wong<sup>1</sup>, Mario Martín-Sánchez<sup>1</sup>, Gabriel M. Leung<sup>1,2</sup>, Benjamin J. Cowling<sup>1,2</sup>,
- 6 Peng Wu<sup>1,2</sup>
- 7

## 8 Affiliations:

- 9 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
- 10 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
- 11 Special Administrative Region, China.
- 12 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology
- 13 Park, New Territories, Hong Kong.
- 14

## 15 **Corresponding author**:

- 16 Ben Cowling: School of Public Health, Li Ka Shing Faculty of Medicine, The University of
- 17 Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong
- 18 Email: <u>bcowling@hku.hk</u>
- 19 Tel: +852-3917 6711
- 20
- 21 **Running head:** Burden of COVID-19 and pandemic responses
- 22 **Keywords:** COVID-19, control, pandemic response, interventions, impact, disease
- 23 burden
- 24 Word count: 269 (Abstract)
- 25 3,859 (Main text)

## 26 ABSTRACT

| 27 | Background: Hong Kong contained COVID-19 for two years, but experienced a large           |
|----|---|
| 28 | epidemic of Omicron BA.2 in early 2022 and endemic transmission of Omicron                |
| 29 | subvariants thereafter.   |
| 30 | Methods: We examined the use and impact of pandemic controls in Hong Kong by              |
| 31 | analysing data on more than 1.7 million confirmed COVID-19 cases and characterizing       |
| 32 | non-pharmaceutical and pharmaceutical interventions implemented from January 2020         |
| 33 | through to 30 December 2022. We estimated the daily effective reproductive number         |
| 34 | $(R_t)$ to track changes in transmissibility and effectiveness of community-based         |
| 35 | measures against infection over time. We examined the temporal changes of                 |
| 36 | pharmaceutical interventions, mortality rate and case-fatality risks (CFRs), particularly |
| 37 | among older adults.   |
| 38 | Findings: Hong Kong experienced four local epidemic waves predominated by the             |
| 39 | ancestral strain in 2020 and early 2021 and prevented multiple SARS-CoV-2 variants        |
| 40 | from spreading in the community before 2022. Strict travel-related, case-based, and       |
| 41 | community-based measures were increasingly tightened in Hong Kong over the first          |
| 42 | two years of the pandemic. However, even very stringent measures were unable to           |
| 43 | contain the spread of Omicron BA.2 in Hong Kong. Despite high overall vaccination         |
| 44 | uptake (>70% with at least two doses), high mortality was observed during the             |
| 45 | Omicron BA.2 wave due to lower vaccine coverage (42%) among adults $\geq$ 65 years of     |
| 46 | age. Increases in antiviral usage and vaccination uptake over time through 2022 was       |
| 47 | associated with decreased case fatality risks.  |
| 48 | Interpretation: Integrated strict measures were able to reduce importation risks and      |
| 49 | interrupt local transmission to contain COVID-19 transmission and disease burden          |
| 50 | while awaiting vaccine development and rollout. Increasing coverage of pharmaceutical     |

- 51 interventions among high-risk groups reduced infection-related mortality and mitigated
- 52 the adverse health impact of the pandemic.
- 53 **Funding**: Health and Medical Research Fund
- 54
- 55 **Key words**: COVID-19; SARS-CoV-2; pandemic preparedness; pandemic responses;
- 56 public health
- 57

# 58 INTRODUCTION

| 59 | The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 led to                    |
|----|--|
| 60 | billions of infections, and more than 17 million deaths had been recorded globally from            |
| 61 | late $2019.^1$ Compared to the most recent influenza pandemic in 2009-2011, significant            |
| 62 | improvements have been made in pandemic responses including surveillance,                          |
| 63 | diagnostics, and innovation and rapid development of vaccines and antivirals. <sup>2</sup> Once    |
| 64 | effective pharmaceuticals became available for SARS-CoV-2, many locations began to                 |
| 65 | transition away from the use of stringent non-pharmaceutical interventions (NPIs) to               |
| 66 | control transmission, given the substantial social and economic costs of sustaining these          |
| 67 | measures. Rapid evolution of SARS-CoV-2 resulted in the emergence of new variants,                 |
| 68 | including Omicron that has dominated the largest waves of global transmission. <sup>3,4</sup> The  |
| 69 | timing and impact of pandemic waves have varied substantially around the world. <sup>5-7</sup>     |
| 70 | Identifying the optimal combination of pharmaceutical and non-pharmaceutical                       |
| 71 | measures at different points in time remains a priority not only for reflecting on the             |
| 72 | response to the COVID-19 pandemic but also for preparing for the next global outbreak.             |
| 73 |  |
| 74 | As a unique case, Hong Kong adopted a stringent containment strategy since 2020, with              |
| 75 | successful control of four local epidemic waves in 2020 and the first half of 2021, and no         |
| 76 | major outbreaks between April and December 2021. However, a large community                        |
| 77 | epidemic of Omicron beginning in January 2022 caused a large number of fatalities                  |
| 78 | within three months, despite the availability of COVID-19 vaccines for over a year by              |
| 79 | that time, and more stringent NPIs being implemented to attempt to contain                         |
| 80 | transmission. <sup>3,8</sup> Here, we systematically examine the progression and control of COVID- |
| 81 | 19 pandemic waves in Hong Kong, focusing on locally adopted control measures and                   |

- 82 their impact on transmission and burden of COVID-19, to identify critical factors in
- 83 response and preparedness over the course of the pandemic.
- 84

## 85 **METHODS**

#### 86 Sources of data

| 87 | We obtained demographic, clinical, and epidemiological data (situation as of 29 January     |
|----|---|
| 88 | 2023) on all laboratory-confirmed and self-reported cases between January 2020 and          |
| 89 | December 2022 from the Hong Kong Department of Health and Hospital Authority of             |
| 90 | Hong Kong. Cases, regardless of symptoms, were recorded as laboratory-confirmed             |
| 91 | when positive by reverse transcription polymerase chain reaction (RT-PCR) tests             |
| 92 | throughout the pandemic and recorded as confirmed based on self-reported positive           |
| 93 | rapid antigen tests (RAT) since 26 February 2022. Confirmed COVID-19 cases were             |
| 94 | classified into mild/moderate, serious, critical, and fatal according to clinical outcomes, |
| 95 | while confirmed cases with available epidemiological information were further               |
| 96 | classified into imported, linked-to-imported, local, and contacts of local cases            |
| 97 | (Appendix).   |
| 98 |   |
|    |   |

99 We classified the COVID-19 pandemic in Hong Kong into six waves by confirmation date 100 of cases. Each wave was divided into pre-peak (16-50 days before peak), peak (15 days 101 before or after peak), and post-peak periods (16-50 days after peak) to reflect the 102 trajectory, where peak was defined as the day recording the largest number of 103 confirmed cases. Waves 5 and 6 were further divided into two periods to reflect 104 changes in healthcare and predominant virus variant over the epidemic, namely 5a (31 105 Dec 2021 - 6 Feb 2022), 5b (7 Feb - 22 May 2022), 6a (23 May - 30 Sep 2022) and 6b (1 106 Oct - 31 Dec 2022). Although the Hong Kong SAR Government classified the resurgence

| 113 | Characterization of non-pharmaceutical interventions                                      |
|-----|---|
| 112 |   |
| 111 | Kong West Cluster.  |
| 110 | Institutional Review Board of the University of Hong Kong/Hospital Authority Hong         |
| 109 | as the sixth wave for clarity and consistency. Our project was approved by the            |
| 108 | because daily cases never declined to zero prior to the resurgence, here we refer to this |
| 107 | of infections in June 2022 with Omicron BA. $4/5$ as a continuation of the fifth wave,    |

- 114 Information on NPIs implemented in Hong Kong was collected through the government
- 115 press releases and classified into travel-related, community-wide, and case-based
- 116 measures (details in Appendix). Travel-related measures include entrance restrictions,
- 117 inbound traveller testing, quarantine, and exemptions. Community-wide measures
- 118 include school closures, work-from-home policies, mask wearing, restrictions on group
- gatherings and measures to reduce crowding and mixing in the population. Case-based
- 120 interventions refer to targeted measures related to case identification, timely isolation,
- 121 and tracing and quarantine of contacts.
- 122
- 123 We used contact tracing data to assess the temporal changes in local case clustering
- 124 patterns. A cluster was defined as at least two RT-PCR confirmed cases with contact
- 125 history and initiated by index local cases (Appendix).<sup>9</sup> We characterized the monthly
- 126 distribution and density distribution of cluster size, stratified by waves.
- 127

## 128 Case finding and contact tracing

129 We obtained data on COVID-19 RT-PCR tests performed in Hong Kong through various

- 130 testing schemes (Appendix) up to wave 5a (7 February 2022),<sup>10</sup> including daily
- 131 numbers of specimens tested and test positives. The testing schemes focused on

| 132 | different risk populations, including inbound travellers, cases and their close contacts,           |
|-----|---|
| 133 | patients in clinical settings, and persons in the general community. We describe                    |
| 134 | temporal changes in testing capacity and case detection proportions and compare the                 |
| 135 | two-week moving average of numbers of specimens collected from close contacts to                    |
| 136 | that from the confirmed cases. We report the distribution of the delays between illness             |
| 137 | onset and case confirmation for symptomatic cases as indicators of the potential impact             |
| 138 | on transmissibility of case finding and isolation across waves, stratified by type of case,         |
| 139 | wave and trajectory.  |
| 140 |   |
| 141 | Population behavioural responses to community-based measures  |
| 142 | To assess population behavioural responses during the COVID-19 pandemic, we                         |
| 143 | conducted 107 rounds of cross-sectional random digit dialling telephone surveys from                |
| 144 | January 2020 to December 2022 (details in appendix). <sup>11,12</sup> Participants reported on face |
| 145 | mask usage, personal hygiene, and social distancing behaviours in the week prior to                 |
| 146 | each survey. We calculated the rim-weighted <sup>11</sup> proportion of respondents who reported    |
| 147 | specific behaviours in each survey, with binomial confidence intervals (CIs).                       |
| 148 |   |
| 149 | We compared community mobility to the pre-pandemic level (1 January 2020) using                     |
| 150 | transaction data on Octopus cards, which is an ubiquitous stored-value and age-                     |
| 151 | stratified payment method for daily public transport. <sup>13</sup> Overall mobility based on all   |
| 152 | card types was calculated and weighted by population age-structure. Changes in                      |
| 153 | community mobility were analysed, stratified by time to the peak of each epidemic                   |
| 154 | wave and age group. We also obtained data from the Immigration Department of Hong                   |
| 155 | Kong to assess changes in inbound travellers during the study period.                               |
| 156 |   |

## 157 **COVID-19** transmission and impact of non-pharmaceutical interventions

| 158 | We extended the approach described by Cori $et  al.^{14}$ to estimate the time-varying                          |
|-----|---|
| 159 | effective reproductive number $(R_t)$ for imported and local cases separately to                                |
| 160 | characterise the transmissibility of COVID-19 (Appendix). $^{15}$ We inferred the epidemic                      |
| 161 | curve by infection date for $R_t$ estimation by applying a deconvolution approach <sup>16</sup> to              |
| 162 | incubation period (mean 5.2 (SD 3.9) days for waves 1-4 and mean 3.5 (SD 2.6) days for                          |
| 163 | waves 5-6) <sup>17,18</sup> , infectiousness relative to onset time <sup>19</sup> and infection-to-report delay |
| 164 | from empirical data. <sup>12</sup>  |
| 165 |   |

166 We examined the impact of combined NPIs ("NPI package") on reducing community 167 transmission by monitoring changes in  $R_t$  for local cases. The inclusion of individual 168 NPIs was informed by the clustering and the variance explained (Appendix). Log-linear 169 regression models were used with daily  $R_t$  as an outcome and interventions as time-170 varying covariates across waves 1 to 5a, allowing for different initial  $R_t$  and effect of 171 work-from-home of each wave. We repeated the above analyses by dropping one wave 172 at each time to test potential changes in NPIs effects across waves.  $R_t$  was estimated for 173 defined NPI packages representing different intensities of interventions and the initial 174 condition as reflected by  $R_t$ , i.e., the initial transmissibility in each wave, in comparison 175 with the scenarios of no NPIs and applying all available NPIs. 95% CIs were estimated 176 using 1,000 bootstraps of coefficient estimates following a multivariate normal 177 distribution.

178

## 179 **COVID-19** fatality and pharmaceutical interventions

180 To characterize the changes in disease burden and severity over wave and trajectory,

181 we used the weekly mortality rate and case-fatality risk (CFR) for the overall population,

| 182 | older adults ≥65 years, and unvaccinated individuals, respectively. Within each group               |
|-----|---|
| 183 | and study period, the weekly mortality rate was calculated as the weekly number of                  |
| 184 | COVID-19 deaths over person-times observed, while the CFR was defined as the number                 |
| 185 | of deaths over the total number of confirmed COVID-19 cases (details in appendix). Data             |
| 186 | from 1 October 2022 onwards were excluded due to potentially reduced ascertainment                  |
| 187 | of COVID-19 cases after that date.  |
| 188 |   |
| 189 | Two vaccines including the inactivated vaccine CoronaVac (Sinovac) and the mRNA                     |
| 190 | vaccine BNT162b2 (BioNTech/Fosun Pharma/Pfizer) were provided for free in Hong                      |
| 191 | Kong starting from February 2021, with third doses available for adults since November              |
| 192 | 2021. We collected age-specific population and daily numbers of vaccine doses                       |
| 193 | administered by age from the territory-wide vaccine registry to calculate the proportion            |
| 194 | fully vaccinated ( $\geq$ 2 doses) among the overall population and older adults $\geq$ 65 years of |
| 195 | age, stratified by wave and trajectory.   |
| 196 |   |
| 197 | Two COVID-specific oral antiviral drugs, molnupiravir (Merck) and                                   |
| 198 | nirmatrelvir/ritonavir (Pfizer) have been authorized for use in Hong Kong since late                |
| 199 | February 2022 and mid-March 2022 respectively. Drug prescriptions for individual                    |
| 200 | patients were used to calculate the proportion of patients who were confirmed by                    |
| 201 | either RT-PCR or RAT and received the antivirals in all ages and unvaccinated older                 |
| 202 | adults $\geq$ 65 years, stratified by wave and trajectory.  |
| 203 |   |

All analyses were conducted in R version 4.0.0 (R Foundation for Statistical Computing,
Vienna, Austria).

206

## 207 **RESULTS**

## 208 Non-pharmaceutical interventions and COVID-19 transmission

- Hong Kong experienced six epidemic waves from January 2020 through December 2022
- 210 (Figure 1, Figure S1 and Table S1), with over 2.6 million laboratory- and RAT-
- 211 confirmed COVID-19 cases (Table 1). Notwithstanding differential ascertainment by
- wave, only 12,631 (0.5%) cases were confirmed during the first four epidemic waves
- 213 predominated by the SARS-CoV-2 ancestral strain, corresponding to 1.6 cases per 1,000
- 214 population. In the second half of 2021, in total there were 841 (98%) imported cases
- but only five sporadic/index local cases reported (Table 1, S2). A superspreading event
- associated with a case of Omicron BA.2.2 who acquired the infection in a quarantine
- hotel initiated a large fifth wave, with a cumulative incidence of 162 cases per 1,000
- 218 persons during January-May 2022 (wave 5), and the incidence rates dropped by 90%

afterwards (Figure 1).

220

The estimated *R<sub>t</sub>* for local infections over the epidemic waves (Figure 1B) indicated that transmissibility of SARS-CoV-2 decreased following (re-)implementation of strict NPIs and rose after relaxation of the measures during the first four waves. In the Omicron BA.2.2 wave (wave 5), *R<sub>t</sub>* remained above 1 even after increasingly stringent control measures were implemented during pre-peak and peak periods (wave 5), and mostly fluctuated at around 1 during the Omicron BA.4/5 wave (wave 6).

227

Hong Kong adopted stringent border controls to prevent importation of cases, including
suspending 12 out of 15 boundary control points, barring entry of non-local residents if
they have been to overseas places, and mandating on-arrival quarantine with RT-PCR
testing in designated facilities for up to 21 days (Figure 1C-D and Table S3-4). We

| 232 | observed a significant decrease in daily passenger arrivals from over 150,000 in January |
|-----|--|
| 233 | to below 3,000 since April 2020 (a 98% decrease from January 2020) and an increase in    |
| 234 | daily COVID-19 testing for inbound travellers from 1,000 in March 2020 to 6,000          |
| 235 | between July and November 2021 (Figures S2-3). As a result, the $R_t$ for imported cases |
| 236 | was maintained well below $1$ since mid-February 2020 (Figure S4) and eventually         |
| 237 | became unquantifiable due to too few sporadic transmission events during the             |
| 238 | following waves (Table 1).   |

239

240 Hong Kong implemented proactive case finding and contact tracing measures, with 241 substantially expanded laboratory testing capacity over time, leading to gradually 242 shortened onset-to-report intervals (e.g., for close contacts of local cases from a median 243 of 5 to 3 days between wave 3 and 5a) (Figures S5-7, Table S5). Quarantine of close 244 contacts were enforced in designated guarantine facilities since January 2020 and home 245 quarantine was introduced since February 28, 2022, and continued until December 28, 246 2022. Numbers of specimens collected from close contacts for testing peaked before the 247 fifth wave, but the ratio to confirmed case numbers decreased substantially compared 248 to previous waves (Figure S5), consistent with widespread community transmission. In 249 clinical settings, testing was required for all pneumonia inpatients and outpatients with 250 respiratory illness since February 2020, and expanded to all hospital admissions in May 251 2020 (Figure 1 and S5). In the community, predefined higher-risk individuals were 252 required to receive regular testing since May 2020, with an increasing contribution to 253 the tested specimens from 40% in the third wave to 88% in wave 5a.

254

The government closed all schools and recommended civil servants to work remotely in
late January 2020 (Figure 1A and Table S2-4). The work-from-home recommendation

| 257 | was removed and re-introduced in subsequent waves, while schools re-opened with       |
|-----|---|
| 258 | restrictions when local cases were low (Figure 1). During the second wave, the        |
| 259 | government instituted infection control requirements for group gatherings, restaurant |
| 260 | capacity and operating hours and other non-essential business sectors in response to  |
| 261 | local case clusters associated with restaurants and bars. These measures were relaxed |
| 262 | and retightened through the following waves. A face mask mandate in all indoor and    |
| 263 | outdoor public areas was issued since the third wave in mid-July 2020 and remained in |
| 264 | place throughout the remaining study period and was only ultimately relaxed in March  |
| 265 | 2023.   |

266

267 Telephone surveys conducted from late January 2020 and December 2022 (total 268 n=82,562) revealed notable behavioural changes in population response to the 269 implemented NPIs. Physical distancing behaviours were observed at high proportions 270 during waves 1-6 especially when local transmission was high (67% to 90%; Figure S8). 271 Face mask use increased to a high level in January 2020 and remained very high (over 272 98%) throughout the study period. Reduced behaviour changes and risk perceptions 273 were observed during the period between wave 4 and 5, and during wave 6 (Figures S8-274 9). There were notable reductions in public transport transactions, with the greatest 275 reductions in wave 5 (largest reduction at 37%, 95% CI, 33% to 40%), compared to 276 previous waves (Figure S10-11). Clusters with more than 10 cases involved were less 277 frequently observed after strict community-based measurements were implemented in 278 the third wave, with a median size of 10 (IQR: 5 to 19) (Figure S12). 279

We included a combination of NPIs that parsimoniously reflected changes in controlling
local transmission in the multivariate analysis (Appendix, Figure S13; adjusted R<sup>2</sup> 67%),

to estimate the effects of different NPI nackages. The NPI nackages adopted in wave 4

|     | co command the encode of american in pachagoes the first pachagoe and provide in marce i   |
|-----|--|
| 283 | appeared to be the strictest among all the waves (Figure 2A). The initial $R_t$ for waves  |
| 284 | 1&2, 3, 4 and 5a were estimated to be 1.2 (95% CI: 1.0 to 1.5), 2.6 (95% CI: 1.9 to 3.5),  |
| 285 | 3.0 (95% CI: 2.3 to 3.9) and 9.3 (95% CI: 6.5 to 13.4), respectively (Figure 3B and Table  |
| 286 | S6). Applying all locally implemented NPIs at the most intensive level was estimated to    |
| 287 | bring $R_t$ down to below 1 (e.g., 0.6, 95% CI: 0.4 to 0.9 for wave 3), except for wave 5a |
| 288 | (3.1, 95% CI: 1.5 to 5.9), while the analysis on the strictest wave-specific NPI packages  |
| 289 | showed that only the NPI package used in wave 4 seemed sufficient to control               |
| 290 | epidemics in waves 1-3, but was only marginally effective during wave 4. However,          |
| 291 | none of the NPI packages from earlier waves could have sufficiently suppressed             |
| 292 | Omicron transmission in wave 5 (Figure 2C).  |
| 293 |  |

- 294 Pharmaceutical interventions against COVID-19
- In total 13,134 COVID-19 deaths were reported throughout the six waves, among which
- 296 74% (n=9,676) were reported between January and May 2023 (wave 5) with a peak in

the overall mortality rate of 2.36 (95% CI, 2.31 to 2.41) deaths per 10,000 person-

weeks (Figure 3-4). Among all fatal cases recorded, 92% (n=12,073) were amongst

299 older adults  $\geq 65$  years of age.

300

282

301 Uptake of the two COVID-19 vaccines in Hong Kong gradually increased during the first

302 six months after having become available, reaching a plateau between October 2021

- and January 2022 (Figure 3). Before wave 5, approximately 70% of the population and
- $304 \quad 42\%$  of older adults  $\ge 65$  years received  $\ge 2$  doses, but fewer than 10% of the whole
- 305 population and fewer than one-tenth of older adults had received a third dose (Figures

306 3-4). The coverage of ≥2 doses of vaccine increased to 82% among adults ≥65 years by
307 the end of wave 6.

308

| 309 | The two antivirals molnupiravir and nirmatrelvir/ritonavir first became available only        |
|-----|---|
| 310 | during the peak of wave 5 and were provided to $18\%$ of the adult patients ≥65y within       |
| 311 | one month (Figures 3-4). The usage of antivirals increased to about $40\%$ among adults       |
| 312 | ≥65y.   |
| 313 |   |
| 314 | The CFR in infected adults $\geq$ 65 years decreased across epidemic waves from 13% (95%      |
| 315 | CI, 11% to 16%) in wave 3 to 0.83% (95% CI, 0.76% to 0.89%) in wave 6 (Figure 4B).            |
| 316 | Following availability of the antivirals, CFRs among unvaccinated adults $\geq$ 65y decreased |
| 317 | from 9.4% (95% CI, 7.5% to 11.6%) pre-peak of wave 5 to 3.0% (95% CI, 2.4% to 3.8%)           |
| 318 | during the peak of wave 6 (Figure 4E). We observed reduced differences in CFRs and            |
| 319 | weekly mortality rate between all and vaccinated adults $\geq$ 65 years along with the        |
| 320 | increasing vaccine uptake in this age group (Figure 4F-G).                                    |
| 321 |   |
| 322 | DISCUSSION  |
| 323 | Using detailed individual case data and territory-wide population data collected during       |
| 324 | the COVID-19 pandemic in Hong Kong, we were able to systematically examine the                |
| 325 | progression of epidemics from 2020-2022 in relation to local pandemic responses,              |
| 326 | including implementation of both NPIs and pharmaceutical interventions over the               |
| 327 | course of the pandemic.   |
| 328 |   |

329 Stringent NPIs aiming to minimize importation risks and interrupt local transmission

330 chains had been implemented in Hong Kong from early in the pandemic, and

| 331 | successfully controlled multiple epidemic waves in the community caused by the                           |
|-----|--|
| 332 | ancestral strain. These measures reduced COVID-19 mortality in a highly susceptible                      |
| 333 | population in the absence of effective pharmaceutical interventions through effectively                  |
| 334 | suppressing the spread of infection. <sup>20</sup> Nevertheless, the containment strategy relying        |
| 335 | solely on NPIs may not be sustainable because of the cost and disruption of these                        |
| 336 | measures. Successful suppression of transmission leaves a large population susceptible                   |
| 337 | to infection with newly emerging, immunologically distinct viral strains, and the NPIs                   |
| 338 | would be less effective in preventing pre-symptomatic and superspreading                                 |
| 339 | transmissions, and in controlling infections with a relatively higher transmissibility. <sup>19,21</sup> |
| 340 | In some countries, relaxation of NPIs resulted in increased COVID-19 mortality. <sup>1,22</sup>          |
| 341 | Achieving high vaccination coverage in the most vulnerable groups, particularly older                    |
| 342 | adults, would minimize COVID-19 mortality after containment measures fail or are                         |
| 343 | relaxed. <sup>23</sup>   |
| 344 |  |
| 345 | Strict travel measures were able to minimize COVID-19 introductions into the                             |

community.<sup>24,25</sup> Despite over 2,000 infections in arriving travellers, only three 346 347 independent introductions accounted for 90% of the local cases between the second 348 and fourth waves.<sup>26</sup> The other cornerstone of the approaches to COVID-19 elimination 349 in Hong Kong was the strict isolation of all confirmed cases until viral shedding of the 350 patients reached low levels before discharge, and quarantine of close contacts identified 351 from contact tracing at designated facilities. While isolation and quarantine likely 352 reduced transmission of COVID-19, it is well recognized that many infections in the 353 community were never confirmed, and a number of community epidemics occurred 354 despite intense contact tracing and timely quarantine.<sup>12</sup> As a consequence, the 355 containment of COVID-19 in Hong Kong cannot be attributed to strict isolation and

356 quarantine alone, while it is clear that moderate social distancing measures were

357 necessary to contain community epidemics with the ancestral strain.

358

| 359 | Community-based physical distancing measures were widely adopted in different parts                |
|-----|--|
| 360 | of the world early in the pandemic, <sup>5</sup> and individual behaviours might have also changed |
| 361 | in response to perceived risk. <sup>27</sup> Our analysis showed that the implementation of        |
| 362 | packages of physical distancing measures, including school closure, working from home              |
| 363 | and suspension of large gatherings, etc., correlated with subsequent decline in the                |
| 364 | effective reproductive number (Figure 2) during epidemics of the ancestral strain but              |
| 365 | these declines were not sufficient to achieve containment of the more transmissible                |
| 366 | Omicron subvariants. It was not possible to estimate the impact from individual                    |
| 367 | measures which were often implemented together.  |
| 368 |  |

369 Containment of COVID-19 in Hong Kong allowed vaccination rollout in early 2021 which 370 could provide an opportunity for a transition/exit strategy from the use of NPIs for 371 containment. Despite over 70% of the Hong Kong population being fully vaccinated by 372 the end of 2021, the vaccine uptake among adults  $\geq 65$  years was low particularly in 373 adults  $\geq 80$  years (approximately 25%) before the Omicron wave. With a high incidence 374 of infections with Omicron, there was a high mortality rate of 1,500 per 1,000,000 375 persons in 2022, the majority of deaths occurring in unvaccinated older adults. 376 Conversely, locations such as Singapore that only considered containment as a 377 temporary approach prior to reaching high vaccination coverage among vulnerable 378 groups recorded much lower mortality rates in their Omicron waves.<sup>5,7</sup> If all adults  $\geq 65y$ 379 were fully vaccinated, a large fraction of deaths in that age group during wave 5 in Hong 380 Kong might have been prevented. The successful control of community transmission for

two years in Hong Kong, and the intention to continue with a containment approach regardless of vaccination uptake, <sup>28</sup> might have contributed to a lack of urgency in increasing vaccination uptake among vulnerable groups,<sup>11,29</sup> further exacerbating the low coverage of vaccine in Hong Kong. Risk communication that address the risk perception and urgency of vaccine uptake, along with convenient outreach vaccination programs, could help to improve vaccine uptake in most vulnerable populations.<sup>11</sup>

388 Planning for "living with the virus" is a challenge for many different locations with 389 different control strategies during the pandemic. Clear objectives in responses are 390 essential for selecting appropriate strategies over the course of the pandemic, and the 391 ultimate goal is always to minimize severe cases and fatalities, and to protect healthcare 392 systems from being overwhelmed. In late 2021, emerging variants such as Delta 393 showing increased immune evasion caused concerns about reduced vaccine-induced 394 protection against infection.<sup>30</sup> However, evidence suggested that COVID-19 vaccines 395 had remained highly effective in preventing severe and fatal outcomes from infections 396 with the variants,  $^{8,31}$  suggesting that vaccination would still likely be an effective way to reduce the severe disease burden even if not preventing infections especially in a 397 398 population with passive immunity conferred by vaccines.<sup>32-34</sup> While Omicron was 399 associated with milder disease and lower impact in some locations,<sup>4</sup> infections may 400 have a similar intrinsic severity to the ancestral virus in persons who have not been 401 vaccinated or previously infected.<sup>35</sup> Real-time risk assessment of emerging variants 402 remains a challenge.

403

404 There are several limitations of our study. First, the investigation of health impact of
405 pandemic control measures did not take into consideration the possible negative effects

| 406 | on economy and quality of life, and the estimates might vary based on local                    |
|-----|--|
| 407 | infrastructure and cultural factors. Second, we estimated the initial transmissibility for     |
| 408 | each epidemic wave, but could not attribute the estimates to viral features or                 |
| 409 | population immunity. However, the increased transmissibility in the fifth wave was             |
| 410 | likely due to increased transmissibility and immune invasion of Omicron variant, due to        |
| 411 | the low seroprevalence and vaccination acquired antibodies in previous waves. <sup>32-34</sup> |
| 412 |  |
| 413 | Experience from Hong Kong has indicated that optimal pandemic control lies in timely           |
| 414 | and efficient implementation of NPIs, along with a high level of population adherence          |
| 415 | before pharmaceutical interventions become available. Once vaccines or antivirals can          |
| 416 | be rolled out, the rationale for continuing to apply disruptive NPIs will gradually            |
| 417 | weaken. Our findings highlight the value of continuously assessing the level of                |
| 418 | population immunity against severe disease in the light of viral evolution and the             |
| 419 | changing availability of pharmaceutical agents. In future pandemics caused by other            |
| 420 | novel respiratory pathogens, employing NPIs as an initial and temporary strategy can           |
| 421 | help to contain the spread, providing time to implement more sustainable control               |
| 422 | measures for high-risk individuals to minimize population mortality and impact on              |
| 423 | public health.   |

# 424 **ACKNOWLEDGMENTS**

- 425 We thank the Department of Health and the Health Bureau (former Food and Health
- 426 Bureau) of the Hong Kong SAR Government for providing the data for the analysis, and
- 427 thank Julie Au and Chloe Chui for technical assistance.
- 428

#### 429 FUNDING

- 430 This project was supported by the Health and Medical Research Fund from the Health
- 431 Bureau of the Hong Kong SAR Government (grant numbers COVID190118 and
- 432 21200212), and the Collaborative Research Scheme (Project No. C7123-20G), the
- 433 Theme-based Research Scheme (Project No. T11-705/21-N) and the General Research
- Fund (Project No. 17110221) from the Research Grants Council of the Hong Kong SAR
- Government. The telephone surveys were supported by the Health and Medical
- 436 Research Fund (ref: COVID19F04, COVID19F11) from the Health Bureau of the Hong
- 437 Kong SAR Government. The funding bodies had no role in the design of the study or in
- 438 the analysis and interpretation of data.

439

## 440 **AUTHOR CONTRIBUTIONS**

- All authors meet the ICMJE criteria for authorship. The study was conceived by BY, GML,
- 442 BJC and PW. Data analyses were conducted by BY, YL, CL, HG, FH, JZ, RZ, WX and TKT.
- 443 BY and PW wrote the first draft of the manuscript, and all authors provided critical
- 444 review and revision of the text and approved the final version.

445

## 446 **COMPETING INTERESTS STATEMENT**

447 BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Pfizer, Roche, and

448 Sanofi Pasteur. The authors report no other potential conflicts of interest.

#### 449 **REFERENCES**

- 450 1. World Health Organization. WHO COVID-19 Dashboard. 2020.
- 451 <u>https://covid19.who.int/</u> (accessed 24 October 2022).
- 452 2. Fineberg HV. Pandemic preparedness and response--lessons from the H1N1
- 453 influenza of 2009. *N Engl J Med* 2014; **370**(14): 1335-42.
- 454 3. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2
- 455 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg Infect Dis* 2022; **28**(9):
- 456 2022.04.07.22273595.
- 457 4. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the
- 458 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet* 2022;
- **399**(10323): 437-46.
- 460 5. Sachs JD, Karim SSA, Aknin L, et al. The Lancet Commission on lessons for the
- 461 future from the COVID-19 pandemic. *Lancet* 2022; **400**(10359): 1224-80.
- 462 6. Sonabend R, Whittles LK, Imai N, et al. Non-pharmaceutical interventions,
- 463 vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling
- 464 study *Lancet* 2021; **398**(10313): 1825-35.
- 465 7. De Foo C, Grépin KA, Cook AR, et al. Navigating from SARS-CoV-2 elimination to
- 466 endemicity in Australia, Hong Kong, New Zealand, and Singapore. *Lancet* 2021;
- **4**67 **398**(10311): 1547-51.
- 468 8. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and
- 469 three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-
- 470 based observational study. *Lancet Infect Dis* 2022.
- 471 9. Adam DC, Wu P, Wong JY, et al. Clustering and superspreading potential of SARS-
- 472 CoV-2 infections in Hong Kong. *Nat Med* 2020; **26**(11): 1714-9.

| 473 | 10. | Young BR. | Yang B. Wu | P. et al. | Residential | clustering | of COVID- | 19 cases and |
|-----|-----|-----------|------------|-----------|-------------|------------|-----------|--------------|
|     |     |           |            | - ,       |             |            |           |              |

- 474 efficiency of building-wide compulsory testing notices as a transmission control
- 475 measure in Hong Kong. *J Infect Dis* 2023.
- 476 11. Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in factors
- 477 associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong:
- 478 Serial cross-sectional surveys. *The Lancet Regional Health Western Pacific* 2022; 23.
- 479 12. Yang B, Tsang TK, Gao H, et al. Universal Community Nucleic Acid Testing for
- 480 Coronavirus Disease 2019 (COVID-19) in Hong Kong Reveals Insights Into Transmission
- 481 Dynamics: A Cross-Sectional and Modeling Study. *Clin Infect Dis* 2022; **75**(1): e216-e23.
- 482 13. Leung K, Wu JT, Leung GM. Real-time tracking and prediction of COVID-19
- 483 infection using digital proxies of population mobility and mixing. *Nature*
- 484 *Communications* 2021; **12**(1): 1501.
- 485 14. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to
- 486 estimate time-varying reproduction numbers during epidemics. *Am J Epidemiol* 2013;
- 487 **178**(9): 1505-12.
- 488 15. Fraser C. Estimating individual and household reproduction numbers in an
- 489 emerging epidemic. *PLoS One* 2007; **2**(8): e758.
- 490 16. Becker DJ, Linebarger DA. Constrained iterative deconvolution applied to
- bearing and amplitude estimation of coherent sources. [1991] Conference Record of the
- 492 Twenty-Fifth Asilomar Conference on Signals, Systems & Computers; 1991 4-6 Nov.
- 493 1991; 1991. p. 579-82 vol 1.
- 494 17. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
- 495 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; **382**(13): 1199-207.

- 496 18. Manica M, De Bellis A, Guzzetta G, et al. Intrinsic generation time of the SARS-
- 497 CoV-2 Omicron variant: An observational study of household transmission. *Lancet Reg*
- 498 *Health Eur* 2022; **19**: 100446.
- 499 19. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and
- 500 transmissibility of COVID-19. *Nat Med* 2020; **26**(5): 672-5.
- 501 20. Pei S, Yamana TK, Kandula S, Galanti M, Shaman J. Burden and characteristics of
- 502 COVID-19 in the United States during 2020. *Nature* 2021; **598**(7880): 338-41.
- 503 21. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19
- outbreaks by isolation of cases and contacts. *Lancet Glob Health* 2020; **8**(4): e488-e96.
- 505 22. Li Y, Campbell H, Kulkarni D, et al. The temporal association of introducing and
- 506 lifting non-pharmaceutical interventions with the time-varying reproduction number (R)
- 507 of SARS-CoV-2: a modelling study across 131 countries. *Lancet Infect Dis* 2021; **21**(2):
- 508 **193-202**
- 509 23. Xiao J, Cowling BJ, Leung GM. Transitioning from covid-19 elimination to
- sustainable endemicity in East Asia. 2021.
- 511 <u>https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-</u>
- 512 <u>sustainable-endemicity-in-east-asia/</u> (accessed 6 May 2023 2023).

513 24. Yang B, Tsang TK, Wong JY, et al. The differential importation risks of COVID-19

- from inbound travellers and the feasibility of targeted travel controls: A case study in
- 515 Hong Kong. Lancet Reg Health West Pac 2021; **13**: 100184.
- 516 25. Yang B, Sullivan SG, Du Z, Tsang TK, Cowling BJ. Effectiveness of International
- 517 Travel Controls for Delaying Local Outbreaks of COVID-19. *Emerg Infect Dis* 2022; **28**(1):
- 518 251-3.
- 519 26. Gu H, Xie R, Adam DC, et al. Genomic epidemiology of SARS-CoV-2 under an
- elimination strategy in Hong Kong. *Nature Communications* 2022; **13**(1): 736.

- 521 27. Du Z, Wang L, Shan S, et al. Pandemic fatigue impedes mitigation of COVID-19 in
- 522 Hong Kong. *Proceedings of the National Academy of Sciences* 2022; **119**(48):

523 e2213313119.

- 524 28. The Economist. Why Hong Kong's 'Zero-covid' strategy could backfire? 2021.
- 525 <u>https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-</u>
- 526 <u>zero-covid-strategy-could-backfire</u> (accessed 26 May 2023 2023).
- 527 29. Yuan J, Lam WTW, Xiao J, Ni YM, Cowling BJ, Liao Q. Why do Chinese older adults
- 528 in Hong Kong delay or refuse COVID-19 vaccination? A qualitative study based on
- 529 Grounded Theory. *The Journals of Gerontology: Series B* 2022: gbac184.
- 530 30. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the
- 531 Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
- 532 31. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-
- 533 CoV-2 Omicron and Delta variants. *Nat Med* 2022; **28**(5): 1063-71.
- 534 32. Boon SS, Wong MCS, Ng RWY, et al. Seroprevalence of Unidentified SARS-CoV-2
- 535 Infection in Hong Kong During 3 Pandemic Waves. *JAMA Netw Open* 2021; **4**(11):
- 536 e2132923.
- 537 33. Poon RW, Chan BP, Chan WM, et al. SARS-CoV-2 IgG seropositivity after the
- severe Omicron wave of COVID-19 in Hong Kong. *Emerg Microbes Infect* 2022; **11**(1):
- 539 **2116-9**.
- 540 34. To KK, Cheng VC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in
- residents evacuated from Hubei province, China: a multicohort study. *Lancet Microbe*
- 542 2020; **1**(3): e111-e8.
- 543 35. Wong JY, Cheung JK, Lin Y, et al. Intrinsic and effective severity of COVID-19
- 544 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong.
- 545 *medRxiv* 2023: 2023.02.13.23285848.

# 546 **FIGURE LEGENDS**

| 547 | Figure 1. Confirmed cases (A), transmission dynamics (B), non-pharmaceutical                  |
|-----|---|
| 548 | interventions (NPIs, C), testing schemes (D), self-reported population behaviours (E),        |
| 549 | and population mobility (F) across the six epidemic waves of COVID-19 in Hong Kong.           |
| 550 | (A) COVID-19 cases. Coloured bars indicated cases laboratory-confirmed by RT-PCR or           |
| 551 | self-reported rapid antigen test (RAT) positives, which were only available after             |
| 552 | February 25, 2022. Laboratory-cases were classified into sporadic/index imported              |
| 553 | (dark blue), linked-to-imported (light blue), sporadic/index local (brown) and contacts       |
| 554 | of local COVID-19 cases (orange). Self-reported RAT positive cases were classified into       |
| 555 | imported (green) or local (pink) cases. Pie charts shows the share of case type for the       |
| 556 | first four waves. ( <b>B</b> ) Estimated effective reproduction numbers $(R_t)$ for local     |
| 557 | transmission based on identified local cases. Shaded areas in dark grey indicated the         |
| 558 | estimated 95% credible intervals of $R_t$ . (C) NPIs taken to suppress and contain the        |
| 559 | Covid-19 transmission in Hong Kong by time. NPIs were classified into three target            |
| 560 | groups: inbound travellers (blue), community (yellow) and case and contact tracing            |
| 561 | (red). Darker shading represents more stringent measures, with details in Table S4. ( $f D$ ) |
| 562 | COVID-19 testing schemes by target groups and settings. Items with asterisks indicate         |
| 563 | testing for individuals with respiratory illness. (E) Population behaviours related to        |
| 564 | physical distancing and personal hygiene measured among the general adult population          |
| 565 | across 107 cross-sectional telephone surveys, January 2020 to December 2022. Point            |
| 566 | estimates (points) and 95% confidence intervals (vertical segments) were estimated by         |
| 567 | each survey. (F) Percentage changes in transport transactions using Octopus cards             |
| 568 | relative to 1 January 2020, weighted by age-structure of Hong Kong population in 2021.        |
| 569 |   |

| 570        | <b>Figure 2</b> . Prediction of effective reproduction numbers $(R_t)$ of COVID-19 associated    |
|------------|--|
| 571        | with non-pharmaceutical interventions (NPIs) taken across epidemic waves. Wave-                  |
| 572        | specific intercepts were used as the baseline level for each epidemic wave. (A) NPIs             |
| 573        | packages used for model prediction: the most stringent measures used in each epidemic            |
| 574        | wave, no measure, and all measures. (B) Wave-specific $R_t$ (row) when no or all                 |
| 575        | measures (column) were implemented. (C) Wave-specific $R_t$ (row) under the most                 |
| 576        | stringent NPIs packages (column) of each epidemic wave.  |
| 577        |  |
| 578        | Figure 3. Confirmed deaths, vaccine coverage, and antiviral usages across the six                |
| 579        | epidemic waves of COVID-19 in Hong Kong. (A) Confirmed COVID-19 deaths sorted by                 |
| 580        | date of confirmation. Coloured bars indicated whether the fatal cases were aged 65               |
| 581        | years or above (red) or otherwise (blue). ( <b>B</b> ) Cumulative coverage of one, two, three or |
| 582        | four doses of CoronaVac and/or BNT162b2. (C) Antiviral usage among confirmed                     |
| 583        | COVID-19 cases aged 65 and above sorted by date of confirmation.                                 |
| 584<br>585 | Figure 4. Disease severity and burden of COVID-19 and implementations of                         |
| 586        | pharmaceutical interventions taken across epidemic waves. Estimates were stratified              |
| 587        | by wave and trajectory. We also calculated the estimates for all Hong Kong population            |
| 588        | (overall), individuals aged 65y and above, and unvaccinated individuals of all ages              |
| 589        | (unvaccinated). (A) Mortality rate per 1000 persons per week. (B) Case-fatality risk.            |
| 590        | Cases were all notified cases, including PCR and RAT positives. (C) Coverage of                  |
| 591        | individuals received two or more doses of COVID-19 vaccines. Vaccine coverage among              |
| 592        | both all Hong Kong (overall; light colours) and individuals aged ≥65y (dark colours)             |
| 593        | were calculated. ( <b>D</b> ) Antiviral usage among confirmed COVID-19 cases aged 65 and         |
| 594        | above. (E) Case-fatality risk and antiviral usage in the fifth and sixth wave. Estimates         |

- 595 were calculated for unvaccinated individuals aged  $\geq$ 65y. (F) Case-fatality risk and
- 596 COVID-19 vaccine coverage in the fifth and sixth wave. We calculated vaccine coverage
- as individuals aged 65 and above and received two or more doses. Case-fatality risk was
- 598 calculated for all adults  $\geq$ 65y and fully vaccinated adults  $\geq$ 65y, respectively. (G)
- 599 Mortality rate and COVID-19 vaccine coverage in the fifth and sixth wave. We calculated
- 600 vaccine coverage as individuals aged  $\geq$ 65y who had received two or more doses.
- 601 Mortality rate was calculated for all adults  $\geq$ 65y and fully vaccinated adults  $\geq$ 65y,
- 602 respectively.

|                             | Wave 1&2   | Wave 3         | Wave 4         | Post wave 4 | Wave 5a        | Wave 5b          |                  | Wav               | e 6a             | Wav              |                  |         |
|-----------------------------|------------|----------------|----------------|-------------|----------------|------------------|------------------|-------------------|------------------|------------------|------------------|---------|
|                             | (1/1/20-   | (1/5/20-       | (1/10/20-      | (1/5/21-    | (31/12/21      | (7/2/22-2        | 22/5/22)         | (23/5/22-         | 30/9/22)         | (1/10/22-        | 31/12/22)        | р       |
|                             | 30/4/20)   | 30/9/20)       | 30/4/21)       | 30/12/21)   | -6/2/22)       | PCR              | RAT              | PCR               | RAT              | PCR              | RAT              |         |
| N                           | 1038       | 4050           | 6682           | 861         | 2804           | 745787           | 449173           | 189298            | 365711           | 222148           | 638080           |         |
| Age group (n, %)            |            |                |                |             |                |                  |                  |                   |                  |                  |                  | < 0.001 |
| 0-18                        | 108 (10.4) | 374 (9.2)      | 591 (8.8)      | 87 (10.1)   | 437 (15.6)     | 62994 (8.4)      | 55915<br>(12.4)  | 18932<br>(10.0)   | 65650<br>(18.0)  | 14726<br>(6.6)   | 107658<br>(16.9) |         |
| 19-29                       | 308 (29.7) | 611 (15.1)     | 931 (13.9)     | 219 (25.4)  | 464 (16.5)     | 85369<br>(11.4)  | 61363<br>(13.7)  | 21395<br>(11.3)   | 48326<br>(13.2)  | 24416<br>(11.0)  | 76807<br>(12.0)  |         |
| 30-44                       | 272 (26.2) | 936 (23.1)     | 1917<br>(28.7) | 315 (36.6)  | 767 (27.4)     | 169209<br>(22.7) | 126669<br>(28.2) | 40886<br>(21.6)   | 101816<br>(27.8) | 52147<br>(23.5)  | 171390<br>(26.9) |         |
| 45-64                       | 269 (25.9) | 1376<br>(34.0) | 2132<br>(31.9) | 203 (23.6)  | 836 (29.8)     | 263295<br>(35.3) | 131810<br>(29.3) | 63887<br>(33.7)   | 105726<br>(28.9) | 78735<br>(35.4)  | 194644<br>(30.5) |         |
| ≥65                         | 81 (7.8)   | 753 (18.6)     | 1111<br>(16.6) | 37 (4.3)    | 296 (10.6)     | 157587<br>(21.1) | 73035<br>(16.3)  | 43719<br>(23.1)   | 43959<br>(12.0)  | 51794<br>(23.3)  | 87069<br>(13.6)  |         |
| Missing                     |            |                |                |             | 4 (0.1)        | 7333 (1.0)       | 381 (0.1)        | 479 (0.3)         | 234 (0.1)        | 330 (0.1)        | 512 (0.1)        |         |
| Sex (n, %)                  |            |                |                |             |                |                  |                  |                   |                  |                  |                  | < 0.001 |
| Male                        | 559 (53.9) | 1960<br>(48.4) | 3134<br>(46.9) | 452 (52.5)  | 1316<br>(46.9) | 366375<br>(49.1) | 193498<br>(43.1) | 91853<br>(48.5)   | 164372<br>(44.9) | 105579<br>(47.5) | 278859<br>(43.7) |         |
| Female                      | 479 (46.1) | 2090<br>(51.6) | 3548<br>(53.1) | 409 (47.5)  | 1484<br>(52.9) | 372618<br>(50.0) | 255512<br>(56.9) | 97021<br>(51.3)   | 201173<br>(55.0) | 116310<br>(52.4) | 358752<br>(56.2) |         |
| Missing                     |            |                |                |             | 4 (0.1)        | 6794 (0.9)       | 163 (0.0)        | 424 (0.2)         | 166 (0.0)        | 259 (0.1)        | 469 (0.1)        |         |
| Case classifications (n, %) |            |                |                |             |                |                  |                  |                   |                  |                  |                  |         |
| Sporadic/index imported     | 616 (59.3) | 664 (16.4)     | 1107<br>(16.6) | 841 (97.7)  | 610 (21.8)     | 1156 (0.2)       | 221 (0.05)       | $18886 \\ (10.0)$ | 2985 (0.8)       | 45286<br>(20.4)  | 6628 (1.0)       |         |
| Linked-to-imported          | 88 (8.5)   | 5 (0.1)        | 11 (0.2)       | 10 (1.2)    | 848 (30.2)     | 56 (0.01)        | 4 (0.001)        | 7 (0.0)           | 30 (0.01)        | 0 (0.0)          | 0 (0.0)          |         |

Table 1. Characteristics of COVID-19 cases confirmed in Hong Kong by epidemic wave.

| Local                                 | 169 (16.3)  | 1293<br>(31.9) | 1795<br>(26.9) | 5 (0.6)    | 485 (17.3) | 740658<br>(99.3) | 448822<br>(99.9) | 170186<br>(89.9) | 362227<br>(99.0) | 176862<br>(79.6) | 631452<br>(99.0) |         |
|---------------------------------------|-------------|----------------|----------------|------------|------------|------------------|------------------|------------------|------------------|------------------|------------------|---------|
| Contact of local                      | 165 (15.9)  | 2088<br>(51.6) | 3769<br>(56.4) | 5 (0.6)    | 861 (30.7) | 3917 (0.5)       | 126 (0.03)       | 219 (0.04)       | 469 (0.1)        | 0 (0.0)          | 0 (0.0)          |         |
| Severity status (n, %)                |             |                |                |            |            |                  |                  |                  |                  |                  |                  | < 0.001 |
| Severe                                | 57 (5.5)    | 495 (12.2)     | 924 (13.8)     | 27 (3.1)   | 69 (2.5)   | 11978<br>(1.6)   | 1511 (0.3)       | 3635 (1.9)       | 1199 (0.3)       | 5753 (2.6)       | 2275 (0.4)       |         |
| Critical                              | 50 (4.8)    | 144 (3.6)      | 211 (3.2)      | 3 (0.3)    | 3 (0.1)    | 1508 (0.2)       | 143 (0.0)        | 435 (0.2)        | 110 (0.0)        | 643 (0.3)        | 248 (0.0)        |         |
| Fatal                                 | 5 (0.5)     | 105 (2.6)      | 102 (1.5)      | 1 (0.1)    | 3 (0.1)    | 8969 (1.2)       | 704 (0.2)        | 682 (0.4)        | 174 (0.0)        | 1661 (0.7)       | 728 (0.1)        |         |
| Delay distribution, days (1           | mean, sd)   |                |                |            |            |                  |                  |                  |                  |                  |                  |         |
| Onset to hospitalization <sup>2</sup> | 5.8 (5.4)   | 4.7 (4.2)      | 3.2 (3.0)      | 2.5 (4.6)  | 2.6 (2.3)  | 5.0 (7.3)        | 11.6(10.4)       | 4.5 (11.4)       | 6.7 (16.3)       | 3.7 (10.1)       | 8.0 (12.3)       | < 0.001 |
| Onset to confirmation                 | 6.5 (5.4)   | 5.2 (3.8)      | 4.3 (3.0)      | 3.7 (4.4)  | 2.8 (1.7)  | 5.5 (5.4)        | 2.3 (4.9)        | 4.6 (41.0)       | 4.2 (5.5)        | 2.7 (12.9)       | 4.2 (35.2)       | < 0.001 |
| Onset to discharge                    | 29.1 (13.2) | 18.6 (14.2)    | 17.3 (15.2)    | 20.9 (9.9) | 14.4 (4.6) | 17.5(20.3)       | 21.5 (17.1)      | 11.3 (14.2)      | 13.0 (18.5)      | 10.1 (11.6)      | 13.1 (13.5)      | < 0.001 |
| Onset to death                        | 36.4 (54.2) | 36 (79.3)      | 29.9 (28.6)    |            | 31.0 ()3   | 11.9 (9.1)       | 17.7 (11.4)      | 14.2 (7.6)       | 14.4 (8.7)       | 16.1 (29.5)      | 15.5 (8.6)       | < 0.001 |
| Confirmation to last positive sample  | 18.0 (12.5) | 10.7 (25.7)    | 9.5 (10.2)     | 10.4 (6.8) | 8.9 (4.6)  | 8.0 (19.1)       | 5.8 (16.6)       | 6.9 (9.0)        | 6.1 (8.3)        | 6.5 (6.5)        | 6.1 (5.9)        | <0.001  |

2 5,215 (1 infection)

<sup>3</sup>Only one case died eventually among all COVID-19 cases confirmed during Wave 5a





















